Wedbush Reaffirms Outperform Rating for iTeos Therapeutics (NASDAQ:ITOS)

iTeos Therapeutics (NASDAQ:ITOS)‘s stock had its “outperform” rating reaffirmed by research analysts at Wedbush in a note issued to investors on Friday,RTT News reports. They currently have a $25.00 price target on the stock. Wedbush’s price objective indicates a potential upside of 222.16% from the company’s previous close.

Several other research analysts have also weighed in on ITOS. Wells Fargo & Company reduced their target price on iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating on the stock in a report on Thursday, December 19th. HC Wainwright reiterated a “buy” rating and issued a $21.00 price objective on shares of iTeos Therapeutics in a research report on Friday, December 13th.

iTeos Therapeutics Stock Down 0.6 %

ITOS stock opened at $7.76 on Friday. The stock has a market cap of $283.50 million, a PE ratio of -2.46 and a beta of 1.39. The firm’s 50-day simple moving average is $8.13 and its 200 day simple moving average is $11.76. iTeos Therapeutics has a fifty-two week low of $7.09 and a fifty-two week high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last issued its earnings results on Tuesday, November 12th. The company reported ($1.05) EPS for the quarter, beating the consensus estimate of ($1.18) by $0.13. Equities analysts forecast that iTeos Therapeutics will post -3.46 EPS for the current fiscal year.

Insiders Place Their Bets

In other iTeos Therapeutics news, CFO Matthew Gall bought 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was acquired at an average price of $7.73 per share, with a total value of $38,650.00. Following the completion of the transaction, the chief financial officer now owns 65,429 shares in the company, valued at approximately $505,766.17. This trade represents a 8.27 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 12.50% of the company’s stock.

Institutional Trading of iTeos Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. nVerses Capital LLC increased its holdings in iTeos Therapeutics by 212.5% during the third quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock worth $26,000 after buying an additional 1,700 shares during the last quarter. Point72 DIFC Ltd bought a new stake in iTeos Therapeutics in the 3rd quarter valued at $31,000. China Universal Asset Management Co. Ltd. boosted its position in shares of iTeos Therapeutics by 60.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock valued at $72,000 after acquiring an additional 2,646 shares during the period. Virtu Financial LLC bought a new position in iTeos Therapeutics during the third quarter worth about $102,000. Finally, Quest Partners LLC increased its position in iTeos Therapeutics by 914.7% during the third quarter. Quest Partners LLC now owns 11,020 shares of the company’s stock worth $113,000 after acquiring an additional 9,934 shares during the period. Institutional investors own 97.16% of the company’s stock.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.